153 related articles for article (PubMed ID: 25433947)
21. The impact of p16 and HER2 expression on survival in patients with ovarian carcinoma.
Shandiz FH; Kadkhodayan S; Ghaffarzadegan K; Esmaeily H; Torabi S; Khales SA
Neoplasma; 2016; 63(5):816-21. PubMed ID: 27468887
[TBL] [Abstract][Full Text] [Related]
22. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
[TBL] [Abstract][Full Text] [Related]
23. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
[TBL] [Abstract][Full Text] [Related]
24. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
25. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
26. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
Rolland P; Deen S; Scott I; Durrant L; Spendlove I
Clin Cancer Res; 2007 Jun; 13(12):3591-6. PubMed ID: 17575223
[TBL] [Abstract][Full Text] [Related]
27. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
29. hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
Wittinger M; Vanhara P; El-Gazzar A; Savarese-Brenner B; Pils D; Anees M; Grunt TW; Sibilia M; Holcmann M; Horvat R; Schemper M; Zeillinger R; Schöfer C; Dolznig H; Horak P; Krainer M
Clin Cancer Res; 2011 Dec; 17(24):7816-27. PubMed ID: 22016507
[TBL] [Abstract][Full Text] [Related]
30. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
31. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
32. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
33. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma.
Shah US; Dhir R; Gollin SM; Chandran UR; Lewis D; Acquafondata M; Pflug BR
Hum Pathol; 2006 Apr; 37(4):401-9. PubMed ID: 16564913
[TBL] [Abstract][Full Text] [Related]
34. EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
Marinaş MC; Mogoş G; Ciurea R; Mogoş DG
Rom J Morphol Embryol; 2012; 53(3):563-7. PubMed ID: 22990547
[TBL] [Abstract][Full Text] [Related]
35. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
[TBL] [Abstract][Full Text] [Related]
36. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma.
Min H; Wei-hong Z
J Obstet Gynaecol Res; 2009 Oct; 35(5):918-25. PubMed ID: 20149042
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
38. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9.
Ji F; Chang X; Liu C; Meng L; Qu L; Wu J; Liu C; Cui H; Shou C
Int J Oncol; 2015 Oct; 47(4):1405-15. PubMed ID: 26251984
[TBL] [Abstract][Full Text] [Related]
40. Loss of fatty acid synthase inhibits the "HER2-PI3K/Akt axis" activity and malignant phenotype of Caco-2 cells.
Li N; Lu H; Chen C; Bu X; Huang P
Lipids Health Dis; 2013 Jun; 12():83. PubMed ID: 23725225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
